Traders Stock tips

One New Stock Market Pick Each Week
To Build Your Winning Stock Trading Profits

HomeThis Weeks Tip | About Our Picks | Market Research

Swing Trading Stocks

STW Biotech Stock
Reports & Analysis
BCRX    EP 4.74
CXM        EP .42
BDSI      EP 2.30
PPHM    EP 1.63
OREX     EP 4.14
ACTC      EP.073
TTNP     EP 1.03
SIGA      EP 6.67
XOMA     EP .46
GNBT       EP .36

Stock Trade of the Day

- Will run to $23+ on
BARDA Contract-Buy 5-16-11

This Weeks Stock Pick

7-6-2010 STW Stock Recommendation ACTC

ACTC may have the largest upside potential of all of the biotechnology stocks priced under $1.00. The technology, scientists and pipeline of this company are outstanding. They not only own a unique patented stem cell extraction method but are working on a drug pipeline that could cure many cases of blindness, double survival rates after heart attacks as well as new program to manufacture blood. The profit potential as well as life changing ability of any one of these would be one of the biggest medical breakthroughs and profit makers of the decade. There is pending news expected in several areas for ACTC including approvals from the FDA and NIH that should lead to a doubling or tripling of the share price in the near term.

ACTC is led by Dr. Lanza who many consider to be greatest mind ever in stem cell research. The only reason we can see for the stock to continue to trade in the .067 to .10 range is the fear of future dilution, but their balance sheet has improved in the past year. They are beginning to get increased non diluting Government funding and are on the verge of having new stem cell lines qualify for more funding in the near future.

TA shows that the share price has likely bottomed and this recent down move after last months price increase on a double dose of good news is simply a correction. We see it as possibly the last opportunity to get in below .08 and are adding to our position. 

Excerpts from Recent Press Releases 

June 16, 2010, WORCESTER, MA – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has been issued U.S. Patent Number 7736896, which is broadly directed to processes developed by ACT scientists for the production of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs). Issued with 35 claims, the patent covers what the company believes are the fundamental methods for producing RPE cells from hESCs in a manner that is suitable for use in human patients. The Company expects to use RPE cells in its Phase I trial to treat patients with Stargardt’s Macular Dystrophy (SMD) and in other pre-clinical applications.

WORCESTER, Mass., Jun 11, 2010 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. /quotes/comstock/11k!actc (ACTC 0.07, -.00, -2.63%) announced today that human embryonic stem cell (hESC) line MA135 was unanimously approved for federal funding at the 100th Meeting of the Advisory Committee to the Director (ACD) National Institutes of Health (NIH). In addition to MA135, seven additional stem cell lines derived at ACT are currently under review by the NIH. Five of these lines were produced without embryo destruction using ACT's proprietary single-blastomere "embryo-safe"

Link to Detailed ACTC Overview from May 2010 Presentation

Information On Dr. Lanza of ACTC

Lanza was born in Boston, Massachusetts. Lanza "altered the genetics of chickens in his basement", and came to the attention of Harvard Medical School researchers when he appeared at the university with his results. Jonas Salk, B. F. Skinner, and Christiaan Barnard mentored Lanza over the next ten years. Lanza attended University of Pennsylvania, receiving BA and MD degrees. There, he was a Benjamin Franklin Scholar, and a Fulbright Scholar.

Lanza was part of the team that cloned the world's first early stage human embryos for the purpose of generating embryonic stem cells and he demonstrated that techniques used in preimplantation genetic diagnosis could be used to generate embryonic stem cells without embryonic destruction. In 2001 he was also the first to clone an endangered species and in 2003, he cloned an endangered wild ox from the frozen skin cells of an animal that had died a quarter-of-a-century earlier.

Lanza and his colleagues were the first to demonstrate that nuclear transplantation could be used to reverse the aging process and to generate immune-compatible tissues, including the first organ grown in the laboratory from cloned cells. Lanza showed that it is feasible to generate functional oxygen-carrying red blood cells from human embryonic stem cells under conditions suitable for clinical scale-up. The blood cells could potentially serve as a source of “universal” blood. His team discovered how to generate functional hemangioblasts from human embryonic stem cells. In animals, these cells quickly repaired vascular damage, cutting the death rate after a heart attack in half and restoring the blood flow to ischemic limbs that might otherwise have required amputatation.  

Current ACTC Programs 

RPE Program

ACT is focused on commercializing its Retinal Pigment Epithelium therapy (RPE) for degenerative retinal disease. The company has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for a human clinical trial to use its RPE cells to treat Stargardt disease, a form of inherited juvenile macular degeneration.

Myoblast program

ACT is developing its Myoblast program, a stem cell therapy for the treatment of chronic heart failure, advanced cardiac disease, myocardial infarction, and ischemia. This program has been approved by the FDA for Phase II clinical trials

Hemangioblast platform

The company is developing its Hemangioblast platform for the treatment of blood and cardiovascular diseases. This program is in the pre-clinical development phase.   

Company Information and Detailed Overview   

Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Operations The company's business is focused on both the development and commercialization of adult stem cell transplantation therapies and embryonic stem (ES) cell based technologies. Its adult stem cell-based products are specifically targeted at therapies for heart and other cardiovascular disease and are at advanced stage of development than its human ES cell based technologies. Human ES Cell Programs The company’s research and technologies are focused on solving this obstacle by creating stem cell therapeutics with compatible tissues. Compatible tissues are referred to as being histocompatible. The company has developed a method to derive human embryonic stem cell lines at the blastomere stage that does not result in the destruction of the preimplantation embryo. Its ES cell technologies are at the level of basic research or in the pre-clinical stage of development. ES Cell Research Programs The company’s ES cell research programs are divided into three core categories: cellular reprogramming, its reduced complexity program, and stem cell differentiation. Cellular Reprogramming: This research program involves development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. These technologies can be used to generate patient-specific pluripotent cells and tissues for transplantation. Its fusion technologies involve the fusion of the cytoplasm of one cell into another. Stem Cell Differentiation: The company intends to pursue differentiation approaches both in-house and through collaborations with other researchers who have particular interests in, and skills related to, cellular differentiation. These efforts include using both animal and human stem cell lines. The company’s research in this area includes projects focusing on developing many different cell types that may be used in the future to treat a range of diseases. The company’s researchers have generated retinal pigment epithelium (RPE) cell lines for use in its clinical retinal program and are working on projects to generate cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. The hemangioblast program is in preclinical development. Adult Stem Cell Program: The company’s adult stem cell-based program is developing an autologous myoblast transplantation therapy delivered using a catheter injection system to restore cardiac function in patients with advanced heart disease. The key target for the therapy would be heart failure patients with New York Heart Association (NYHA) scores Class II to IV. The company’s transplantation therapy involves extraction through biopsy from a patient's thigh of myoblasts, which are non-embryonic, skeletal muscle stem cells that can be expanded in culture and injected back into damaged and scarred regions of the heart. It has received approval to proceed with its Phase II clinical trial, to evaluate the applications for myoblast transplantation in slowing and/or reversing the impact of heart failure.

ACTC Stock Chart and Technical Analysis

Price Channel
ACTC is trading above the lower end of its price channel indicating a short term bottom has been established.

The chart shows that ACTC has maintained the positive direction of momentum even though the price has fallen. This indicates a correction nearing its end and is a bullish signal.

The Stochastic Oscillator is registering a weak bullish signal as the %K has crossed above the %D. However, the oscillator is currently below the critical value of 20, identifying ACTC as oversold. An oversold condition means that the recent downwards momentum is not sustainable. Investors should watch for the oscillator to move above 20 which will increase the bullishness of this signal.

On Balance Volume
The On Balance Volume indicator (OBV) shows that longer term selling pressure has given way to near term accumulation.

Price Channel
ACTC is trading near its lower price channel band. This suggests that the stock price is low relative to the action over the last 5 day period.

Ultimate Oscillator
The Ultimate Oscillator is currently at 35.18% which indicates that the stock is neither overbought nor oversold. You should note the trend of the Ultimate Oscillator to see if the internal strength of ACTC is improving or weakening.

STW is long ACTC

STW Biotech
Stock Watch List



Sign Up
For STW Email
Trading Alerts



| HomeThis Weeks Tip | About Our Picks | Market research | Privacy-Terms |©2006-2010      Contact:      Website Managed by TRM Daytona Beach, Florida

This website is for information purposes only. All stock market investments have risk and may increase or decline. The management of this site is not responsible for any profit or loss you experience, do your own due diligence an any company before investing, our stock tips are only a starting point, you are ultimately responsible for your own investment decisions.